Please login to the form below

Not currently logged in

India should create pharmaceutical ministry

Minister Sujan Chakraborty of the Communist Party of India has suggested the creation of a separate department or ministry for the pharmaceutical sector.

Minister Sujan Chakraborty of the Communist Party of India has suggested the creation of a separate department or ministry for the pharmaceutical sector.

In a letter to Prime Minister Manmohan Singh, Chakraborty identified that the prices of pharmaceutical products manufactured in the country were attractive to the international market and the Third World. He added that there was scope for greater cooperation between India and other developing countries.

In the letter, Chakraborty said that the national common minimum programme of the United Progressive Alliance government has laid emphasis on health, especially for poor and rural people.

"You will agree that the success of the National Rural Health Mission is interrelated with rapid development of the indigenous pharmaceutical sector," stated Chakraborty.

He drew attention to the problem of the large number of authorities controlling the Indian pharmaceutical sector and warned that the potential for rapid development was not being harnessed properly.

"The sector has to be clear about the nodal ministry or department. There should be clear-cut responsibility for identifying constraints of the sector and for providing help to overcome them," advised Chakraborty.

The Indian pharmaceutical industry is estimated to be worth USD 12bn and ranks 17th in terms of value of export. In 2006-07, the industry achieved a growth rate of approximately 19 per cent for drugs and pharmaceutical items.

Around 37 per cent of pharmaceutical technologists in the US are of Indian origin and many leading Indian manufacturers have either set up establishments in the US or in the EU and have had their products approved by the FDA and other regulatory bodies.

In July and August 2007, Indian courts have denied incremental innovation patents to a number of international pharmaceutical companies looking to develop drugs in the region. As a result, some, such as Swiss-based Novartis, have withdrawn proposed R&D investment programmes.

30th September 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

OPEN Health Graduates and the XP Support Group
During our graduate induction period in September 2018, we were asked to find a charity that could benefit from the expertise of the OPEN Health practices. We made the decision...
Alexander Devine Website has gone live!
As part of the OPEN Health CSR programme one of the charities we support is Alexander Devine. They are a local Children's Hospice based in Maidenhead who provide a truly...
Drug pricing and competition
Strengthening business competition and reducing anti-competitive practices
How the CMA is tackling high prices for essential drugs...